image dons

I make a donation

ARMADA

Effects of Enoxaparine, Dalteparine and NFH on the activation markers of red blood cells in patients presenting an unstable angor or an acute coronary syndrome

Terminée

Colloquium "Rythme et conduction" (23 avril 2024)
Inscrivez-vous !

La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

logo étude

objectif

Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction.

date de réalisation

2001

nombre de patients

141

nombre de centres participants

Monocentric

type de financement

Private (Sanofi-Aventis)

Publication

  • Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study)
    Gilles Montalescot, Claire Bal-dit-Sollier, Daniela Chibedi, Jean-Philippe Collet, Thierry Soulat, Miles Dalby, Rémi Choussat, Ariel Cohen, Michel Slama, Phillipe-Gabriel Steg, Jean-Luc Dubois-Randé, Jean-Philippe Metzger, François Tarragano, Jean L Guermonprez, Ludovic Drouet, ARMADA Investigators
    Publicated in The American Journal of Cardiology

Autres études

+

ARAMIS

En cours


Evaluation of Anakinra versus placebo in treatment of acute myocarditis and evaluation of the contuity of the reference treatment with IEC in patients without ventricular dysfunction ventriculaire.
+

AFLOAT

En cours


To assess if flecainide is more efficient than standard of care (control group) to prevent AF occurrence during the 3 months after PFO closure.
+

BIO-TAVI

En cours


Correlation between the platelet reactivity, the von Willebrand factor and bleeding and thrombotic events occuring during the year following TAVI